TRPM6 and its homologue TRPM7 are α-kinase-coupled divalent cation-selective channels activated upon reduction of cytosolic levels of Mg2+ and Mg·ATP. TRPM6 is vital for organismal Mg2+ balance. However, mechanistically the cellular role and functional nonredundancy of TRPM6 remain incompletely understood. Comparative analysis of native currents in primary cells from TRPM6- versus TRPM7-deficient mice supported the concept that native TRPM6 primarily functions as a constituent of heteromeric TRPM6/7 channels. However, heterologous expression of the human TRPM6 protein engendered controversial results with respect to channel characteristics including its regulation by Mg2+ and Mg·ATP. To resolve this issue, we cloned the mouse TRPM6 (mTRPM6) cDNA and compared its functional characteristics to mouse TRPM7 (mTRPM7) after heterologous expression. Notably, we observed that mTRPM6 and mTRPM7 differentially regulate properties of heteromeric mTRPM6/7 channels: In the presence of mTRPM7, the extreme sensitivity of functionally expressed homomeric mTRPM6 to Mg2+ is tuned to higher concentrations, whereas mTRPM6 relieves mTRPM7 from the tight inhibition by Mg·ATP. Consequently, the association of mTRPM6 with mTRPM7 allows for high constitutive activity of mTRPM6/7 in the presence of physiological levels of Mg2+ and Mg·ATP, thus laying the mechanistic foundation for constant vectorial Mg2+ transport specifically into epithelial cells.
Transient receptor potential melastatin 6 (TRPM6) and 7 (TRPM7) are extraordinary proteins comprising two distinct functional moieties: an ion channel segment and an α-type serine/threonine kinase domain1, 2. Experiments with TRPM7-deficient cell lines revealed that TRPM7 regulates salient cell processes such as Mg2+ metabolism3,4,5, Ca2+ signaling6,7,8, chromatin modification9, cell motility10,11,12,13, proliferation6,7,8, 14,15,16 and differentiation17,18,19. Genetic inactivation of Trpm7 in mice results in early embryonic death17, 19. Conditional tissue-specific inactivation of Trpm7 in mice showed that TRPM7 plays a critical role in morphogenesis of various internal organs19,20,21. In contrast to global Trpm7 null mutations, specific genetic inactivation of the kinase activity (referred to a ‘kinase-dead’ Trpm7 mutation) does not impede embryonic development22. Adult ‘kinase-dead’ Trpm7 mice are more resistant to dietary Mg2+ deprivation in terms of survival and develop a mild form of organismal Mg2+ deficiency23. These results were interpreted to mean that the TRPM7 kinase moiety is necessary for an adaptive systemic response to Mg2+ deficiency23. Recently, a search for genetic forms of macrothrombocytopenia in humans resulted in the discovery of two pedigrees harbouring loss-of-function point mutations in the human TRPM7 gene24. These patients presented with impaired thrombopoiesis due to altered cellular Mg2+ homeostasis and cytoskeletal architecture24.
Recombinant TRPM7 proteins from several vertebrate species have been cloned and functionally characterized2. With minor exceptions25, key channel properties of TRPM7 orthologues were found to be highly conserved. Briefly, recombinant TRPM7 forms homotetrameric channel complexes highly permeable to Ca2+, Mg2+ and Zn2+ 15, 26,27,28. Intracellular and extracellular Mg2+ regulates TRPM7 channel activity. External Mg2+ acts as a permeant blocker of the channel pore15, 26,27,28,29. Internally applied Mg2+ ([Mg2+]i) and Mg·ATP ([Mg·ATP]i) inhibit TRPM7 currents15. Accordingly, cytosolic concentrations of Mg·ATP and free Mg2+ have been suggested as key feedback regulators of TRPM7 function implying that depletion of intracellular Mg2+ and Mg·ATP promotes TRPM7-mediated uptake of extracellular Mg2+ 15. TRPM7 is assumed to be a ubiquitously expressed protein2, and endogenous TRPM7 currents, referred to as magnesium nucleotide-regulated metal ion currents (MagNuM)15, 30 and magnesium-inhibited cation currents (MIC)31, have been detected in all cell types examined so far2.
Loss-of-function mutations in the human TRPM6 gene give rise to autosomal recessive hypomagnesemia, also called primary hypomagnesemia type 1, intestinal (HOMG1) or hypomagnesemia with secondary hypocalcemia (HSH)32,33,34,35. HSH manifests in early infancy with 3- to 10-fold decreased serum Mg2+ concentrations, generalized convulsions and muscle spasms. Relief of clinical symptoms can be achieved by administration of high doses of Mg2+ 32,33,34,35. Unexpectedly, Trpm6 null mice die at embryonic day 12.5 (e12.5)36. Recently, our group employed a set of newly generated mouse strains to define the in vivo role of TRPM637. We showed that TRPM6 activity in extraembryonic cells of the placenta and yolk sac is essential for embryonic survival of mice37. In adult mice, TRPM6 is required in intestinal epithelial cells to maintain organismal Mg2+ balance37. Thus, TRPM6 is a central gatekeeper of organismal Mg2+ balance in mammals, and its role cannot be compensated by any other channel such as TRPM7. Against the backdrop of the Mg2+-permeable ubiquitously expressed TRPM7, the pivotal role of TRPM6 in transporting epithelia is only incompletely understood.
In contrast to the situation with TRPM7, functional characterization of the TRPM6 channel for the most part relies on experiments with the human TRPM6 (hTRPM6) cDNA. Our group38, 39 and other investigators40, 41 observed that hTRPM6 does not efficiently form homomultimeric channels in the plasma membrane, but requires TRPM7 to be co-targeted to the cell surface38, 39. Within heteromeric channel complexes (referred to TRPM6/7 channels), hTRPM6 increases the current amplitude of TRPM6/7 heteromers as compared to TRPM7 homomers38, 39. According to other authors42, 43, overexpressed hTRPM6 was able to form homomeric channels with biophysical characteristics resembling those of TRPM7 including the high channel pore selectivity for divalent cations and regulation by [Mg2+]i and [Mg·ATP]i. More recently, it has been reported that expression of recombinant hTRPM6 gives rise to functional channels only if the hTRPM6 cDNA was inserted into the pCINeo-IRES-GFP vector (referred to pCINeo-hTRPM6-IRES-GFP), whereas the same cDNA sequence placed in various other expression plasmids did not yield functional hTRPM6 channels27. This feature of hTRPM6 appears to be unique among TRP proteins, and is still lacking any mechanistic explanation. Furthermore, different researchers used the same pCINeo-hTRPM6-IRES-GFP construct to report contradictory results regarding the sensitivity of hTRPM6 to [Mg·ATP]i, ranging from full suppression in the presence of physiological levels of [Mg·ATP]i 44 to complete insensitivity27. Hence, the functional characteristics of recombinant TRPM6 require further clarification.
In light of the latter controversy, we opted for the functional analysis of primary cells lacking the endogenous mouse TRPM6 (mTRPM6) protein rather than for heterologous expression models and employed trophoblast stem (TS) cells derived from Trpm6- and Trpm7-gene deficient mouse blastocysts37. We found that wildtype TS cells express both mTRPM6 and mTRPM7, thus mirroring the in vivo situation in transporting epithelial cells invariably co-expressing both proteins. We showed that wildtype TS cells exhibit TRPM7-like currents, and that genetic inactivation of mTRPM6 reduces the amplitude of these currents. Ionic currents in mTRPM6-deficient TS cells were substantially more sensitive to [Mg·ATP]i but equally affected by [Mg2+]i 37. In contrast, deletion of mTRPM7 resulted in complete disappearance of TRPM7-like currents in TS cells37. These findings support the concept that native TRPM6 primarily functions as a subunit of heteromeric TRPM6/7 channels and that [Mg·ATP]i most likely is a crucial endogenous regulator of Mg2+ uptake mediated by TRPM6/7 channels.
In the present paper we investigated the role of channel and kinase domains of TRPM6 for the sensitivity of TRPM6/7 channels to [Mg2+]i and [Mg·ATP]i. Because the functional consequences of the heterologous expression of hTRPM6 are surrounded by considerable controversy, we cloned and functionally characterized mTRPM6. Our experiments show that the functional hallmarks of recombinant mTRPM6 in HEK 293 cells recapitulate key findings that emerged from the comparative assessment of mTRPM6- and mTRPM7-deficient TS stem cells37, lending credence to the concept that the association of mTRPM6 with mTRPM7 substantially alters the regulatory properties of the mTRPM6/7 channels such as their sensitivity to cytosolic Mg·ATP. As a consequence, mTRPM6/7 channels display the unique property of remaining constitutively active in the presence of physiological levels of cytosolic Mg2+ and Mg·ATP. Hence, the association of mTRPM6 with mTRPM7 will likely lead to a constant Mg2+ uptake, thus providing a mechanistic explanation for efficient Mg2+ transport into epithelial cells only in the presence of mTRPM6.
Cloning and functional expression of recombinant mTRPM6 cDNA
Mus musculus is broadly used as an in vivo experimental model to study the physiological role of ion channels including TRPM6 and TRPM7. Surprisingly, the murine TRPM6 protein has not been investigated so far in heterologous expression systems. To resolve the discrepancies obtained with heterologous expression of human TRPM6, we cloned the mouse TRPM6 cDNA into pIRES2-EGFP vector and assessed its channel and kinase activities upon transient expression in HEK 293 cells. We generated a full-length mTRPM6 cDNA (NCBI accession KX375810) using RNA extracted from lung tissue. Sequencing confirmed that the obtained mTRPM6 cDNA contains an open reading frame (ORF) encoding a 2028-amino acid protein, showing 100% protein sequence identity to an NCBI predicted sequence NM_153417.1. Similar to hTRPM645, mTRPM6 comprises a highly conserved N-terminal TRPM domain and a typical TRP-like channel segment followed by a C-terminal kinase moiety (Fig. 1A). We used a previously reported crystal structure of the mTRPM7 kinase46 to generate a 3D model of the mTRPM6 kinase domain and the location of residues critical for the catalytic activity of the TRPM6 kinase such as K1810 (K1646 in mTRPM7) (Fig. 1B)3, 45. In addition, we predicted a residue that is likely to be autophosphorylated in mTRPM6 such as T1730 (S1567 in mTRPM747) (Fig. 1B).
To evaluate these predictions functionally, we generated mTRPM6 cDNA variants carrying a ‘kinase-dead’ point mutation (mTRPM6-K1810R) and a variant lacking the predicted autophosphorylation site (mTRPM6-T1730A). Next, we transiently expressed wildtype mTRPM6, mTRPM6-K1810R and mTRPM6-T1730A constructs in HEK 293 cells and assessed the expression levels of the recombinant proteins by Western blot analysis (Fig. 1C). In these experiments, we used a rabbit polyclonal antibody designed as a specific probe for mTRPM6 phosphorylated at T1730 ((p)T1730-specific antibody), and a guinea pig anti-TRPM6 polyclonal (ab47017) antibody to identify all mTRPM6 variants. We observed that the ab47017 antibody detected comparable protein expression of wildtype mTRPM6, mTRPM6-K1810R and mTRPM6-T1730A and that mTRPM6-specific bands were of the expected size (232 kDa) (Fig. 1C). The (p)T1730-specific antibody only detected wildtype mTRPM6, but not the mutant variants (Fig. 1C) consistent with the notion that the kinase domain autophosphorylates the mTRPM6 protein at position T1730 and that the K1810R mutation ablates the catalytic activity of mTRPM6 kinase. Consequently, we asked whether the catalytic activity of mTRPM6 kinase can be manipulated in living cells by pharmacological agents. Previously, Davis et al.48 examined 442 kinases to assess the overall selectivity of 72 well-defined kinase inhibitors. The authors reported that TG100-115 inactivated the purified kinase domain of hTRPM648. We observed that a 12-h culture of mTRPM6-transfected HEK 293 cells in the presence of TG100-115 led to suppression of (p)T1730 immunoreactivity (Fig. 1D). Thus, both the K1810R mutation and TG100-115 enable to block mTRPM6 kinase.
Assessment of mTRPM6 currents in HEK 293 cells and in trophoblast stem cells
HEK 293 cells were transiently transfected with either mTRPM6 or mTRPM7 cDNAs inserted into the pIRES2-EGFP expression vector and EGFP-positive cells were examined by patch-clamp analysis. Whole-cell currents were elicited by a voltage ramp protocol ranging from −100 to +100 mV and a Mg2+-free internal solution (Fig. 2A). In HEK 293 cells expressing mTRPM7, outward and inward current amplitudes were small immediately after establishing the whole-cell configuration, but rapidly increased presumably due to depletion of intracellular Mg2+. mTRPM7 currents reached a plateau after ~100 s (Fig. 2A). The current-voltage (I-V) relationships of mTRPM7 currents exhibited characteristic features such as small inward and large outward currents with a pronounced rectification, and a reversal potential of about 0 mV (Fig. 2C). Notably, mTRPM6-expressing cells also developed inward and outward currents (Fig. 2A) with an I-V relationship resembling that of mTRPM7 (Fig. 2C). However, other biophysical characteristics of mTRPM6 currents were distinct: While mTRPM6 currents reached a peak at ~100 s of recording, they gradually declined thereafter presumably due to an intrinsic inactivation mechanism (Fig. 2B). Furthermore, we noted that fully developed outward and inward mTRPM6 currents were substantially (~3-fold) smaller when compared to values obtained with mTRPM7 (Fig. 2D).
It has been shown that the endogenous hTRPM7 protein is expressed in HEK 293 cells, and that native TRPM7-like currents can be measured in this cell line15, 49. Potentially, the native hTRPM7 protein may form heteromeric channel complexes with recombinant mTRPM6 and thus contaminate our recordings. Indeed, we were able to elicit mTRPM7-like currents in untransfected HEK 293 cells (Fig. 2A,B). However, amplitudes of these endogenous currents were ~10-fold smaller than those in mTRPM6-expressing HEK 293 cells (Fig. 2D), suggesting that the currents measured in mTRPM6-transfected cells could not solely be attributed to the activity of endogenous hTRPM7.
Next, we asked whether mTRPM6 channel activity could be measured in the cells deficient in mTRPM7. To address this question, we used recently generated trophoblast stem (TS) cells derived from Trpm7 null mouse blastocysts37. As reported previously37, Trpm7-deficient TS cells completely lack native TRPM7-like currents (Fig. 2E,F). We found that transient overexpression of mTRPM6 resulted in whole-cell currents similar to mTRPM6 currents attained in HEK 293 cells. Hence, upon transient overexpression of recombinant protein, activity of homomeric mTRPM6 channel was measurable independently of the presence of endogenous TRPM7 channels.
It has been reported27 that transient expression of human TRPM6 (hTRPM6) gives rise to a functional channel only if hTRPM6 cDNA is inserted into a specific expression vector, whereas the same cDNA clone placed in other expression plasmids did not yield functional hTRPM6 channels27. We could fully recapitulate this finding (Supplementary Fig. S1). Thus, in analogy to the previous study27, transient transfection of the pCINeo-hTRPM6-IRES-GFP expression construct allowed us to detect hTRPM6 currents, well comparable to mTRPM6 currents (Supplementary Fig. S1A). However, when investigating a HEK 293 T-REx cell line stably expressing hTRPM627, 50, we found that doxycycline-induced cells displayed currents undistinguishable from endogenous currents measured in uninduced cells (Supplementary Fig. S1B). Consequently, we asked whether functional expression of mTRPM6 cDNA would also be dependent on the expression system employed. We subcloned the mTRPM6 cDNA into the frequently used pcDNA3.1 vector38 and co-transfected this construct with a small amount of EGFP cDNA into HEK 293 cells. Patch-clamp analysis of EGFP-positive HEK 293 cells (Supplementary Fig. 2A) revealed currents very similar to those detected in cells transfected with pIRES2-mTRPM6-EGFP (Fig. 2B), suggesting that expression vectors are interchangeable for functional assessment of the mTRPM6 cDNA. In our follow-up experiments we used the pIRES2-mTRPM6-EGFP and pIRES2-mTRPM7-EGFP constructs.
Cation permeability of mTRPM6
TRPM7 channel is highly permeable to a range of divalent cations including Ca2+, Mg2+ and Zn2+ 15, 26. Therefore, we asked whether the cation permeation profile of mTRPM6 differs from that of mTRPM7. In a first set of experiments, we assessed the permeation block of mTRPM7 currents by extracellular divalent cations, a well-known characteristic feature of TRPM715, 26. As expected, exposure of mTRPM7-expressing cells to a divalent cation-free (DVF) solution entailed large monovalent cation currents with a characteristic linear I-V relationship (Fig. 3A). These monovalent mTRPM7 currents were stable over the whole time of exposure. After wash-out, this characteristic response of mTRPM7 was fully reversed (Fig. 3A). We also noted that the endogenous TRPM7-like currents reliably recapitulated functional properties of recombinant mTRPM7 (Fig. 3B). In contrast, mTRPM6-transfected cells only showed an initial TRPM7-like response to the application of DVF solution, characterized by prompt increases of outward and inward currents (red traces; Fig. 3C) followed by a fast, irreversible inactivation of mTRPM6 activity (green traces; Fig. 3C). Hence, unlike the situation with mTRPM7, the removal of external divalent cations relieved the mTRPM6 channel from the divalent cation permeation block followed by the fast rundown of channel activity.
Divalent cation selectivity of TRPM7 has been determined by two means: (i) by shifts in the reversal potential of monovalent TRPM7 currents to more positive values after application of external solutions containing individual divalent cations15, 26, 29, and (ii) by changes of inward currents in cells exposed to external solutions containing only divalent cations15, 26, 29. Since a reliable assessment of the reversal potential of monovalent mTRPM6 currents was not possible (Fig. 3C), we used the second option as outlined in Fig. 4 and Fig. 5. We induced mTRPM7 and mTRPM6 currents using standard internal and external solutions containing 1 mM CaCl2 and 2 mM MgCl2. When currents were developed, cells were exposed to external solutions containing 10 mM of individual specific divalent cations (Zn2+ is poorly soluble above 10 mM at pH 7.0). To prevent Na+ from passing through the channels along with divalent cations, external monovalent cations were replaced by the non-permeant N-methyl-D-glucamine (NMDG). Similar to a previous study26, the exposure of mTRPM7-transfected cells to 10 mM Zn2+ caused a ~3-fold increase in inward currents (Fig. 4A). The perfusion of cells with 10 mM Mg2+ or 10 mM Ca2+ led to a modest, but statistically significant reduction of inward currents (Fig. 4B,C). Thus, in accord with previous publications15, 26, 29, mTRPM7 showed a higher permeability for Zn2+ as compared to Mg2+ and Ca2+ under these experimental conditions. Corresponding experiments with mTRPM6 expressing cells showed that mTRPM6 is also highly permeable to Zn2+ as the application of Zn2+-based external solution caused a ~2-fold increase of inward currents (Fig. 5A). Unlike mTRPM7, however, inward currents of mTRPM6 increased upon exposure of 10 mM Mg2+ (Fig. 5B) and were unaltered in the presence of 10 mM Ca2+ (Fig. 5C) indicating that the mTRPM6 channel is more permeable to Mg2+ as compared to Ca2+.
Finally, we tested whether mTRPM6 is also permeable to nonabundant trace cations such as Ba2+ (Supplementary Fig. S3). In line with a previous study26, we observed that the exposure of mTRPM7-transfected cells to 10 mM Ba2+ caused an increase in outward and inward currents (Supplementary Fig. S3A). In contrast, only outward currents of mTRPM6 were elevated in the presence of 10 mM Ba2+ (Supplementary Fig. S3B), suggesting that the mTRPM6 channel is less permeable to Ba2+ as compared to mTRPM7. To summarize, our experiments show that the divalent cation permeation profile of mTRPM6 is similar, but not identical to that of mTRPM7.
High sensitivity of mTRPM6 currents to intracellular Mg2+
A remarkable feature of the TRPM7 channel is its high sensitivity to physiological levels of cytosolic Mg2+ ([Mg2+]i) and Mg·ATP ([Mg·ATP]i)15, 26, 27, 51. Therefore, we compared the effects of [Mg2+]i and [Mg·ATP]i on mTRPM6 and mTRPM7 currents using solutions containing various concentrations of free Mg2+ and Mg·ATP. In initial experiments, we studied mTRPM7 currents in the presence of 1 µM free [Mg2+]i (Fig. 6A,F). In line with previous reports15, 26, 27, 51, we observed no inhibitory effect of 1 µM free [Mg2+]i on mTRPM7 (Fig. 6A,F) and only a moderate suppression of endogenous TRPM7-like currents (Fig. 6B,F). Surprisingly, we found that currents in mTRPM6-transfected cells did not develop at all in the presence of 1 µM [Mg2+]i (Fig. 6C,F). Consistently, mTRPM6 overexpressed in mTRPM7-deficient TS cells was also inactive in the presence of 1 µM free [Mg2+]i (Supplementary Fig. S2B). Furthermore, even when we applied a nominally [Mg2+]i-free intracellular solution (Fig. 6D,F), cells transfected with mTRPM6 cDNA failed to develop any currents indicating that mere traces of free Mg2+ are sufficient to block mTRPM6. Such unexpected sensitivity of mTRPM6 to Mg2+ prompted us to examine the influence of 1 µM [Mg2+]i on currents in HEK 293 cells transfected with pCINeo-hTRPM6-IRES-GFP (Supplementary Fig. S1A). We found that hTRPM6 currents were not affected by 1 µM [Mg2+]i (Supplementary Fig. S1A), indicating that the high sensitivity of mTRPM6 to cytosolic Mg2+ can be attributed to the mTRPM6 channel itself rather than to the experimental conditions used. Since known Mg2+ chelators, such as EDTA or EGTA, do not allow to reliably prepare a saline solution containing [Mg2+]i in the nM range, we did not attempt to obtain concentration-response data for mTRPM6 currents.
It has been suggested that the catalytic activity of the TRPM7 kinase domain regulates the sensitivity of the TRPM7 channel to [Mg2+]i and [Mg·ATP]i 51. Therefore, we asked whether the kinase activity of mTRPM6 might be responsible for the high sensitivity of mTRPM6 to [Mg2+]i. To address this question, we examined cells transiently expressing the ‘kinase-dead’ mTRPM6-K1810R variant (Fig. 1B) and found that mTRPM6-K1810R remained inactive in the presence of 1 µM [Mg2+]i, but could be induced using the standard [Mg2+]i-free intracellular pipette solution (Fig. 6E,F). We conclude that the kinase activity of mTRPM6 is not involved in the strong inhibitory effect of [Mg2+]i on the mTRPM6 channel activity.
In a physiological saline solution, the apparent Kd of Mg·ATP is 50 ± 10 µM52 implying that cytosolic Mg·ATP will always co-exist with a certain amount of free Mg2+ sufficient to block mTRPM6 regardless of the actual content of Mg·ATP. To test this assumption, we compared the effects of a relatively low concentration of [Mg·ATP]i (210 µM) on mTRPM7 and mTRPM6. We observed that mTRPM7 currents were partially inhibited by Mg·ATP (Fig. 7A,E). Interestingly, endogenous TRPM7-like currents were only modestly affected under these conditions (Fig. 7B,E). As expected, 210 µM [Mg·ATP]i strongly suppressed currents in wild-type mTRPM6 and mTRPM6-K1810R transfected cells (Fig. 7C–E). Hence, mTRPM6 displays an extraordinarily high sensitivity to cytosolic Mg2+ independent of the catalytic activity of its kinase domain.
Functional characterization of heteromeric mTRPM6/7 channel complexes
Our experiments with recombinant mTRPM6 suggest that homomeric mTRPM6 channels, if formed in the cell, will most likely be inactive in the presence of physiological concentrations of cytosolic Mg2+ (Fig. 6), which are estimated to be in the range of 0.3–1 mM53, 54. Previously, we suggested38, 39 that the native TRPM6 protein primarily exists as a subunit of heteromeric channel complexes formed by TRPM6 and TRPM7 (TRPM6/7). Consequently, we asked whether such a paradoxical Mg2+ sensitivity of mTRPM6 would look different in mTRPM6/7 complexes. To address this question, we co-transfected mTRPM6 and mTRPM7 expression constructs in HEK 293 cells. Western blot analysis of cell lysates revealed that co-expression of mTRPM6 had no effect on the expression levels of mTRPM7 (Supplementary Fig. S4). Next, we used an immunoprecipitation approach to show that mTRPM6 is able to associate with mTRPM7. mTRPM7 fused to a myc tag (mTRPM7-myc) was expressed in HEK 293 cells either alone or co-expressed with mTRPM7, mTRPM6 and mTRPM5 containing a YFP tag (mTRPM7-YFP, mTRPM6-YFP and mTRPM5-YFP, respectively). mTRPM7-myc was solubilized and immunoprecipitated using an anti-myc antibody. Both cell lysates and immunoprecipitates were subjected to SDS-gel electrophoresis and subsequent immunoblotted with an anti-GFP antibody (cross-reacting with YFP) or anti-myc antibody (Supplementary Fig. S5). As expected, we detected mTRPM7-myc in the cell lysates and immunoprecipitates (Supplementary Fig. S5). In addition, mTRPM7-myc immunoprecipitates contained mTRPM7-YFP and mTRPM6-YFP, but not a more distantly related channel, mTRPM5-YFP (Supplementary Fig. S5). Hence, in line with our previous findings with hTRPM638, 39, mTRPM6 can assemble with mTRPM7 in heteromeric channel complexes.
Next, we performed patch-clamp experiments with HEK 293 cells co-transfected with mTRPM6 and mTRPM7 cDNA constructs. In initial experiments, we assessed the currents induced by standard [Mg2+]i-free internal solution (Fig. 8A). We found that cells co-transfected with 1 µg mTRPM6 and 1 µg mTRPM7 cDNA constructs displayed mTRPM7-like currents substantially larger than cells transfected with 2 µg mTRPM7 cDNA alone (Fig. 8A). In addition, we noted that all cells transfected with mTRPM6/7 cDNAs exhibited large currents already at break-in (Fig. 8B). I-V relationships of these pre-activated currents (Fig. 8B) were indistinguishable from those of fully developed currents (Fig. 8A). In contrast, all solely mTRPM7 expressing cells displayed very small currents after break-in (Fig. 8B). Further analyses revealed that amplitudes of pre-activated currents of mTRPM6/7 were ~10-fold larger than corresponding values obtained with mTRPM7 expression (Fig. 8B) and were comparable with fully activated currents (at 90 s) of mTRPM6 homomers (Fig. 2B). Of note, such constitutive channel activity was not observed in experiments with untransfected HEK 293 cells (Fig. 2B) or in cells transfected by mTRPM6 alone (Fig. 2A). These findings indicate that in resting cells heteromeric mTRPM6/7 channels were active prior to manipulation of intracellular [Mg2+]i and [Mg·ATP]i via the patch pipette. Consequently, we asked whether such high constitutive activity of mTRPM6/7 can be attributed to an increased expression of mTRPM6 or mTRPM7 protein in the plasma membranes of cells co-transfected with both constructs as compared to cells expressing only mTRPM6 or mTRPM7. To this end, we isolated the plasma membrane proteins from cells transfected with mTRPM6 or mTRPM7 and from cells co-transfected with mTRPM6 and mTRPM7 cDNA (Supplementary Fig. S6). Western blot analysis revealed that the plasma membrane levels of mTRPM6 and mTRPM7 protein in co-transfected cells were reduced as compared to cells expressing only mTRPM6 or mTRPM7 (Supplementary Fig. S6). Hence, the high channel activity of mTRPM6/7 is unlikely caused by an increased expression of heteromeric channels in the plasma membrane, but represents a qualitative hallmark of mTRPM6/7.
Next, we examined the concentration-dependent suppression of currents by [Mg2+]i (Fig. 8C, Supplementary Table S1). Cells expressing mTRPM6/7 exhibited larger current amplitudes over the whole range of [Mg2+]i examined (P ≤ 0.0001, F-test). Compared to mTRPM7, we noted only a modest, but statistically significant rightward shift of the concentration-response curve of mTRPM6/7 currents. Thus, the calculated IC50 value for mTRPM7 currents was 1.29 mM. Currents in mTRPM6/7 expressing cells were inhibited by [Mg2+]i with an IC50 value of 1.55 mM (P ≤ 0.001, F-test). These results suggest that mTRPM7 in mTRPM6/7 complexes offsets the exquisite Mg2+ sensitivity of mTRPM6 to physiological levels of cytosolic Mg2+.
Next, we asked whether mTRPM6/7 would be active in the presence of Mg·ATP. Physiological concentrations of [Mg·ATP]i vary between 2–7 mM in most mammalian cells53, 54. First, we studied the effects of relatively high levels of Mg·ATP (Fig. 9A). We found that 9 mM [Mg·ATP]i entailed nearly complete suppression of mTRPM7 channel activity. In contrast, mTRPM6/7 currents were only modestly inhibited by 9 mM [Mg·ATP]i (Fig. 9A). Concordant with experiments shown in Fig. 8B, we observed ~10-fold higher channel activity in mTRPM6/7 expressing cells immediately after break-in (Fig. 9B). Next, we compared the concentration-dependent suppression of mTRPM6/7 and mTRPM7 currents by [Mg·ATP]i (because of experimental limitations, effects of [Mg·ATP]i higher than 10 mM could not be reliably examined). [Mg·ATP]i suppressed mTRPM7 currents with an IC50 value of 2.93 mM (Fig. 9C, Supplementary Table S2). In contrast, mTRPM6/7 complexes were characterized by a remarkably low sensitivity to [Mg·ATP]i at all concentrations examined (P ≤ 0.0001, F-test). Such a weak effect of [Mg·ATP]i on mTRPM6/7 currents did not allow for a reliable calculation of an IC50 value. Nevertheless, the concentration-response data indicate that more than 15 mM [Mg·ATP]i are required to reduce mTRPM6/7 currents by ~50% (Fig. 9C), suggesting that, in stark contrast to mTRPM7, physiological levels of [Mg·ATP]i will exert only a minor (if any) inhibitory effect on mTRPM6/7 currents.
It has been proposed that the catalytic activity of the hTRPM6 kinase domain regulates the sensitivity of the hTRPM6/7 channels to [Mg·ATP]i 27 . Therefore, we investigated whether the kinase-inactivating K1810R mutation in mTRPM6 would shift the [Mg·ATP]i sensitivity of the mTRPM6/7 channels into the mTRPM7-like range. We examined cells transiently expressing mTRPM6-K1810R and wildtype mTRPM7 and found that mTRPM6-K1810R behaved similarly to wildtype mTRPM6. Specifically, we found that the standard Mg2+-free internal solution induced mTRPM6-K1810R/7 currents (Supplementary Fig. S7) comparable to values displayed by the wildtype mTRPM6/7 channels (Fig. 8A) and that the ‘kinase-dead’ mutation did not offset the low sensitivity of heteromeric channels to 9 mM [Mg·ATP]i (Supplementary Fig. S7). We conclude that the catalytic activity of the mTRPM6 kinase is unlikely to play a major role in this regulatory mechanism.
Finally, we studied whether mTRPM6 and mTRPM6/7 respond differentially to small synthetic molecules acting as activators or inhibitors of the mTRPM7 channel55. We first examined the effect of NS8593, a potent mTRPM7 inhibitor49, on mTRPM6 currents (Supplementary Fig. S8A). In this experiment, we induced mTRPM6 currents using a Mg2+-free pipette solution and externally applied 10 µM NS8593 when mTRPM6 currents were fully developed. We noted that NS8593 caused a rapid irreversible inhibition of mTRPM6 (Supplementary Fig. S8A). Next, we assessed effects of naltriben, a potent agonist of mTRPM7 channel56. In these experiments, we used intracellular solutions containing 2 mM [Mg2+]i for mTRPM7, whereas mTRPM6 currents were evaluated in the presence of a [Mg2+]i-free solution or saline containing 1 µM fee [Mg2+]i. As expected, the external application of 50 µM naltriben led to a fast stimulation of mTRPM7 currents (Supplementary Fig. S8B). Unlike mTRPM7, mTRPM6 did not respond to 50 µM naltriben, neither in the presence of 1 µM [Mg2+]i nor in Mg2+-free conditions (Supplementary Fig. S8C). It has been reported that 2-aminoethyl diphenylborinate (2-APB) acts as a positive modulator of hTRPM6 and an inhibitor of hTRPM727, 43. In our experimental settings, 200 µM 2-APB reversibly blocked mTRPM7 currents (Supplementary Fig. S9A). In contrast, 200 µM 2-APB potentiated mTRPM6 currents (Supplementary Fig. S9B). Hence, mTRPM6 displays distinct responses to naltriben and 2-APB. Consequently, we asked how these compounds affect mTRPM6/7 currents. We observed that naltriben (50 µM) could modestly potentiate mTRPM6/7 currents, but these changes were not statistically significant (Supplementary Fig. S8D). 200 µM 2-APB triggered a moderate, slow and irreversible rundown of mTRPM6/7 currents (Supplementary Fig. S9C). Taken together, our study offers a set of endogenous and exogenous agents enabling to distinguish mTRPM6, mTRPM7 and mTRPM6/7 currents.
Here we employed a newly cloned mTRPM6 cDNA to provide further evidence in support of the previously suggested concept that native TRPM6 functionally interacts with TRPM7 to maintain transcellular Mg2+ transport37,38,39. We show that mTRPM6 and mTRPM7 differentially contribute to regulatory characteristics of heteromeric mTRPM6/7 channel complexes: mTRPM7 is able to offset the very high sensitivity of mTRPM6 to cytosolic Mg2+ to physiologically relevant concentrations, whereas mTRPM6 relieves mTRPM7 from inhibition by Mg·ATP. Consequently, in contrast to mTRPM7, the activity of mTRPM6/7 channels will hardly be affected by physiological intracellular concentrations of Mg2+ and Mg·ATP. Such a functional fingerprint is most likely not critical for metabolic processes in resting cells, but this mechanism appears to be an indispensable prerequisite for efficient transcellular Mg2+ transport in placental and intestinal epithelial cells i.e. when a high and constant uptake of extracellular Mg2+ should be uncoupled from the cellular metabolism of Mg2+ and Mg·ATP.
TRPM6 is inevitably co-expressed with the ubiquitously present TRPM7 and the mechanism of the non-redundant role of TRPM6 for organismal Mg2+ balance is subject to considerable debate. Previously, our group extensively studied recombinant expression of hTRPM6 in HEK 293 cells and in Xenopus oocytes38, 39. Regardless of the experimental system and plasmid backbone used, we observed that hTRPM6 homomultimers are retained in intracellular membrane compartments. However, co-expression of hTRPM6 and mTRPM7 resulted in co-trafficking of TRPM6/7 channels to the cell surface38,39,40. Current amplitudes of TRPM6/7 complexes were found to be higher than those of TRPM7 homomers38, 39. The assembly of recombinant heteromeric TRPM6/7 channel complexes was demonstrated by fluorescence resonance energy transfer (FRET) and co-immunoprecipitation approaches as well as by functional analysis of channel subunits carrying a dominant-negative point mutation in the pore-forming segment38,39,40. More recently, we investigated placental trophoblast stem (TS) cells isolated from gene-modified mice37. We observed that a disruption of native mTRPM6 resulted in a reduction of current amplitudes, whereas deletion of mTRPM7 caused complete ablation of endogenous currents. Remarkably, the currents in mTRPM6-deficient TS cells were considerably more sensitive to intracellular Mg·ATP37. These findings are consistent with a recent study of Zhang et al.57 elucidating the contribution of hTRPM6 and hTRPM7 to endogenous currents in human neuroblastoma SHEP-21N cells, and with work of Ryazanova et al. examining native currents in mouse embryonic stem (ES) cells expressing mTRPM6 and mTRPM75. The latter reports also showed that genetic ablation of mTRPM7 led to full suppression of TRPM7-like currents. Hence, the functional analysis of native currents entertains the notion that native TRPM6 functions as a subunit of TRPM6/7 complexes where it increases current amplitudes and relieves TRPM7 from inhibition by [Mg·ATP]i.
However, it should not go unnoticed that other researchers claimed that hTRPM6 can function independently of TRPM742,43,44. The latter proposition is based on the finding that transient transfection of pCINeo-hTRPM6-IRES-GFP expression constructs (but not other expression vectors27) allows to detect channel activity of hTRPM6 homomultimers. Interestingly, experiments with pCINeo-hTRPM6-IRES-GFP yielded remarkably different results concerning the sensitivity of hTRPM6 to [Mg2+]i and [Mg·ATP]i. Thus, one group reported that hTRPM6 is suppressed by [Mg2+]i and [Mg·ATP]i with IC50 values of 510 µM and 1.3 mM, respectively42, 44. In contrast, another laboratory observed that pCINeo-hTRPM6-IRES-GFP evoked currents that were completely insensitive to 3–9 mM [Mg·ATP]i, whereas [Mg2+]i efficiently blocked hTRPM6 currents with a physiologically irrelevant IC50 of 29 µM27. The reasons for such discrepancies still remain unclear. In particular, there is no sensible argument as to why only one specific expression plasmid should allow for functional expression of hTRPM6.
Since the functional characteristics of heterologously expressed hTRPM6 are surrounded by considerable controversy, we focussed on a newly isolated murine TRPM6 clone. We noted that recombinant mTRPM6 homomultimers could be functionally expressed irrespective of the vector backbone used. Although such an overexpression system does not fully recapitulate the properties of native mTRPM6 (e.g. endogenous mTRPM6 at rather low protein levels is active only in the presence of mTRPM737), this in vitro model may be instrumental in dissecting functional hallmarks of the kinase and channel activity of mTRPM6 upon co-expression with recombinant mTRPM7. We noted that overexpression of mTRPM6 in HEK 293 cells yielded currents significantly (~3-fold) smaller than mTRPM7 currents. In contrast to mTRPM7, mTRPM6 currents rapidly inactivated, especially when the mTRPM6 expressing cells were exposed to monovalent cation-based external solutions. We also noted that the mTRPM6 channel is more selective for Zn2+ as compared to Mg2+, Ca2+ and Ba2+, resembling the ion permeation profile of mTRPM7. Surprisingly, the mTRPM6 channel was found to be highly sensitive to cytosolic Mg2+: mTRPM6 was inactive even in the presence of a nominally Mg2+-free intracellular solution. The catalytic activity of the mTRPM6 kinase does not appear to play a role in the channel’s high sensitivity to [Mg2+]i. In this context, our findings are in accord with results of Zhang et al. showing supressed hTRPM6 currents in the presence of non-physiologically low concentrations of [Mg2+]i (IC50 of 29 µM)27. Therefore, mTRPM6 as well as hTRPM6 homomers, if formed, will be inactive in the presence of physiological levels of cytosolic Mg2+ or [Mg·ATP]i.
Finally, we examined how mTRPM6 may modulate the response of mTRPM7 to [Mg2+]i and [Mg·ATP]i. We noted that cells co-transfected with mTRPM6 and mTRPM7 displayed currents amplitudes significantly larger than cells only harbouring recombinant mTRPM7, mimicking the situation in TS cells37. Of note, mTRPM6/7 channels displayed high channel activity immediately after break-in of the patch, suggesting that mTRPM6/7 complexes are constitutively active in the presence of steady-state cytosolic concentrations of Mg2+ and Mg·ATP. In line with this concept, we observed that, contrary to mTRPM7, mTRPM6/7 currents were only slightly inhibited by physiological levels of [Mg·ATP]i (3–9 mM) and were significantly more active in the presence of physiological [Mg2+]i levels (0.5–1 mM). These findings are concordant with the study of Zhang et al. reporting that hTRPM6/7 heteromers are not sensitive to 9 mM [Mg·ATP]i 27 and additionally with our assessment of native currents in TRPM6- vs TRPM7-deficient TS cells37. Moreover, we found that the catalytic activity of the mTRPM6 kinase does not contribute to the low sensitivity of the mTRPM6/7 channels to [Mg·ATP]i. Lastly, mTRPM6/7 displayed differential responses to small organic compounds such as naltriben and 2-APB as compared to mTRPM6 or mTRPM7.
To summarize, our findings indicate that mTRPM6 and mTRPM7 contribute differentially to key functional characteristics of mTRPM6/7 complexes thereby functionally defining a new type of channel that remains active in the presence of physiological concentrations of [Mg2+]i and [Mg·ATP]i. Consequently, mTRPM6/7 channels will be able to maintain a constant supply of Mg2+ for the organism regardless of the actual metabolic state of epithelial cells. In contrast, the channel activity of mTRPM7 homomers is tightly controlled by cytosolic levels of [Mg2+]i and [Mg·ATP]i and, thus, closely linked to cellular metabolism. Such a mechanistic model provides a plausible answer for the hitherto open question as to why in transporting epithelia TRPM6 function cannot be replaced by other ion channels including TRPM7.
Molecular biology, in silico analysis and cell culture
In the course of NCBI GenBank data mining, a predicted mRNA sequence of Mus musculus Trpm6 gene was identified (NM_153417.1) and was therefore used for cloning of a full-length Trpm6 cDNA. TRIzol reagent (Thermo Fisher Scientific) was used for extraction of total RNA from the whole lung of C57BL/J mice and SuperScript II reverse transcriptase (Thermo Fisher Scientific) for first strand synthesis. The Expand High Fidelity polymerase enzyme system (Roche) was used for PCR amplification of different overlapping segments of the predicted TRPM6 ORF. We used the following primer pairs: mM6for1 5′-GAGAATGCAGGTCAAGAAGCAATC-3′ and mM6rev3 5′-TGCCCACAGTCCCATCAT-3′ with PCR settings: 94 °C 3′, 94 °C 30″, 55 °C 30″, 72 °C 1′, 35 cycles, 72 °C 5′ (PCR product 752 bp encompassing exons 1–7 of Trpm6); mM6for2 5′-TGCCCTAAAAGCCCATTCCTCTAA-3′ and mM6rev4 5′-CGTCCCCCTCTTCCTGGTCCTGT-3′ with PCR settings: 94 °C 3′, 94 °C 30″, 58 °C 30″, 72 °C 3′, 35 cycles, 72 °C 5′ (PCR product 2873 bp corresponding to exons 2–24 of Trpm6); mM6for3 5′-ATGGCGCCTGGCTCGTGACA-3′ and mM6rev2 5′-ACCACCGTCTTCCTTCATCATCTTTTT-3′ with PCR settings: 94 °C 3′, 94 °C 30″, 58 °C 30″, 72 °C 4′, 35 cycles, 72 °C 5′ (PCR product 3077 bp comprising sequence of exons 22–39 of Trpm6). The obtained PCR products were inserted into pcDNA3.1 vector by a TOPO-cloning approach (pcDNA3.1/V5-His TA-TOPO kit, Thermo Fisher Scientific) and confirmed by sequencing (Eurofins Genomics, Ebersberg, Germany). Next, the full-length Trpm6 cDNA (NCBI accession KX375810) was generated by in-frame subcloning of the latter cDNA fragments either in pcDNA3.1 or in pIRES2-EGFP (Clontech) expression vectors using standard molecular biological techniques. Translation in silico (DNASTAR Lasergene software) of the cloned TRPM6 cDNA produced a 2028-aa ORF that matched to the predicted ORF sequence in NM_153417.1. 3D model of the TRPM6 kinase domain structure were generated as reported previously29, 39 using MODELLER (modbase.compbio.ucsf.edu/modweb) and UCSF Chimera (www.cgl.ucsf.edu/chimera).
K1810R and T1730A point mutations in mTRPM6 cDNA (both in pIRES2-EGFP vector) were introduced by site-directed mutagenesis (QuikChange, Stratagene). To generate mTRPM6 with a C-terminal myc tag in the pcDNA3.1/V5-His TA-TOPO vector (mTRPM6-myc) and with a C-terminal yellow fluorescent protein (YFP) tag in pcDNA3.1/V5-His TA-TOPO vector (mTRPM6-YFP), a STOP codon in the mTRPM6 cDNA was replaced by a SalI restriction site through site-directed mutagenesis followed by in-frame sub-cloning of myc or YFP coding sequence as reported previously26, 43. All generated mTRPM6 cDNA variants were verified by sequencing.
mTRPM7 (in pIRES2-EGFP vector), mTRPM7-myc (in pcDNA3.1/V5-His TA-TOPO vector) and mTRPM7-myc (in pcDNA3.1/V5-His TA-TOPO) were reported previously29, 38, 58. mTRPM5-YFP (in pcDNA3.1/V5-His TA-TOPO) was described earlier59, 60. Likewise, the hTRPM6 expression construct (pCINeo-hTRPM6-IRES-GFP) has been reported before27, 42.
Human embryonic kidney (HEK) 293 cells were grown at 37 °C and 5% CO2 in Eagle’s minimum essential medium (MEM, Sigma Aldrich) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific), 100 U/ml penicillin and 100 µg/ml streptomycin (P/S, Sigma-Aldrich). Cells were transiently transfected by 2 µg expression constructs using Lipofectamine 2000 reagent (Thermo Fisher Scientific). In some experiments, 1 µg of mTRPM6 and 1 µg mTRPM7 cDNA constructs were co-transfected in HEK 293 cells. Patch-clamp experiments were performed 20–24 h after transfection. Successfully transfected cells were identified by their green fluorescence when illuminated at 480 nm.
The HEK-293 T-REx cell line stably expressing hTRPM6 was cultured as reported previously27, 50. hTRPM6 overexpression was induced by adding 1 µg/ml doxycycline (Thermo Fisher Scientific) to the growth medium. Patch-clamp experiments were performed 20–24 h after induction.
Transient expression of mTRPM6 in Trpm7-deficient trophoblasts stem (TS) cells
Trpm7-gene deficient TS cells were generated as described before37. TS cells were incubated in a humidified cell culture incubator (Heraeus, Thermo Fisher Scientific) at 37 °C and 5% CO2 in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 20% fetal bovine serum (ES type, Thermo Fisher Scientific), 1 mM sodium pyruvate (cell culture type, Sigma-Aldrich), 100 µM β-mercaptoethanol (Sigma-Aldrich), 50 µg/ml streptomycin and 50 U/ml penicillin (Thermo Fisher Scientific), 1.0 µg/ml heparin (cell culture type, Sigma-Aldrich), 25 ng/ml human recombinant FGF4 (R&D systems), 5 ng/ml human recombinant TGF-β1 (R&D systems), 10 ng/ml recombinant activin A (R&D systems) and an additional 10 mM MgCl2. For transient expression of mTRPM6, 1 × 105 TS cells were electroporated with 2 µg cDNA by applying two voltage pulses (1000 V, 30 ms) using Neon Transfection System (Thermo Fisher Scientific). The TS cells were studied 24 h after electroporation.
Generation of (p)T1730 mTRPM6-specific antibody and Western blot analysis
To generate a polyclonal (p)T1730 mTRPM6-specific antibody, rabbits were immunized with a phosphorylated peptide AcNH-RLSQ(p)TIPFTPIQC-CONH2 coupled via its C-terminal cysteine residue to keyhole limpet hemacyanin (Eurogentec, Belgium). The generated serum was subjected to two rounds of peptide affinity chromatography. First, a fraction of antibody was purified using the phosphorylated peptide. Second, the isolated antibody was followed by an additional round of chromatography using a non-phosphorylated variant of the peptide (AcNH-RLSQTIPFTPIQC-CONH2) in order to deplete a fraction of antibody with cross-reactivity to a non-phosphorylated mTRPM6 protein. The final fraction of anti-(p)T1730 mTRPM6 antibody was aliquoted and stored at −80 °C.
To assess the mTRPM6 kinase activity, the anti-(p)T1730 mTRPM6 antibody was used to probe cell lysates obtained from HEK 293 transiently transfected with mTRPM6 cDNA variants. In some experiments (Fig. 1D) transfected cells were cultured for 12 h in the presence of TG100–115 (Absource Diagnostic GmbH). The lysis buffer (Pierce IP Lysis Buffer, Pierce) contained protease inhibitor and phosphatase inhibitor cocktails (Biotool). Aliquots of the cell lysates were mixed (1:1) with 2x Laemmli buffer, heated at 70 °C for 10 min and cooled on ice. The samples were separated by SDS-PAGE (6% acrylamide/bis-acrylamide, Carl Roth) and electroblotted on nitrocellulose membranes (GE Healthcare Life Science). After blocking with 5% (w/v) non-fat dry milk in Tris-buffered saline with 0.1% Tween 20 (TBST), the membranes were probed by (p)T1730 mTRPM6-specific antibody (1 µg/ml in TBST with 5% (w/v) BSA), followed by washing in TBST, incubation with a horseradish peroxidase-coupled anti-rabbit lgG (Cell Signaling Technology; 1:1000 in TBST with 5% (w/v) non-fat dry milk) and washing again in TBST. Blots were exposed in a luminescence imager (Peqlab/VWR, Germany). Expression levels of mTRPM6 were examined using a guinea pig anti-mTRPM6 polyclonal antibody (ab47017, Abcam; 1:4000) and a horseradish peroxidase-coupled anti-guinea pig lgG (Acris; 1:1000). Western blot assessment of mTRPM7 was performed analogously to mTRPM6 using a rabbit anti-TRPM7 monoclonal antibody (EPR4582, Abcam; 1:2000).
To assess expression levels of mTRPM6 and mTRPM7 in the plasma membranes, HEK 293 cells cultured in 100-mm cell culture dishes (~70% confluency) were transiently transfected with 10 and 20 µg mTRPM6, 10 and 20 µg mTRPM7 or co-transfected with 10 µg mTRPM6 together with 10 µg mTRPM7 (all in pIRES2-EGFP vector). 24 h after transfection, cells were collected by centrifugation and the cell pellets were washed twice with ice-cold PBS. Plasma membrane proteins were extracted using the MinuteTM plasma membrane protein isolation kit (Invent Biotechnologies) according to the manufacturer’s protocol. The obtained samples of plasma membrane proteins (50 μl) were mixed with 50 μl 2x Laemmli buffer, heated at 70 °C for 10 min and cooled on ice. Next, Western blot analysis of mTRPM6 and mTRPM7 (1/3 of the plasma membrane samples) was performed as described above. The plasma membranes marker Na+/K+ ATPase was probed using an anti-Na+/K+ ATPase antibody (EP18459-HRP, Abcam; 1:5000).
Co-immunoprecipitation of mTRPM7 and mTRPM6
Experiments were performed as reported previously61 with several modifications. HEK 293 cells maintained in 100-mm cell culture dishes (~70% confluency) were transiently transfected with 10 µg mTRPM7-myc, 10 µg mTRPM6-YFP and 10 µg mTRPM5-YFP or co-transfected with 10 µg mTRPM7-myc together with 10 µg mTRPM7-YFP, mTRPM6-YFP and mTRPM5-YFP expression constructs. 24 h after transfection, cells were lysed in 1 ml of ice-cold lysis buffer (1 ml of PBS supplemented with 1% Triton X-100 and a protease inhibitor cocktail). Cell lysates were centrifuged at 4 °C (10 min at 10,000 × g; 1 h at 30,000 × g) and 900 μl of the supernatants were further mixed with an anti-myc 9E10 antibody (M5546, Sigma-Aldrich) immobilized on Protein A/G magnetic beads (88802, Thermo Fisher Scientific). For immobilization, 2 μl anti-myc antibody was incubated with 20 μl (0.2 mg) Protein A/G magnetic beads in 1 ml of the lysis buffer overnight at 4 °C. Afterwards, magnetic beads were washed three times in 1 ml lysis buffer at 4 °C, collected using a magnetic stand, passed to the cell lysates (900 μl) and incubated overnight at 4 °C. Next, beads were washed three times in 1 ml lysis buffer, collected using a magnetic stand, re-suspended in 100 μl 2x Laemmli buffer, heated at 70 °C for 10 min and cooled on ice. 1/5 of the immunoprecipitate samples and aliquots of the cell lysates (10 μl mixed with 10 μl 2x Laemmli buffer) were subjected to Western blot analysis as described above using an anti-GFP antibody (ab290, Abcam; 1:1000 in TBST with 5% (w/v) BSA) or anti-myc antibody (9B11, Cell Signaling Technology; 1:1000 in TBST with 5% (w/v) BSA).
Patch clamp experiments were performed as reported previously49, 62, 63 with a few modifications. Whole-cell currents were measured using an EPC10 patch-clamp amplifier and PatchMaster software (Harvard Bioscience). Voltages were corrected for a liquid junction potential of 10 mV. Currents were elicited by a ramp protocol from −100 mV to +100 mV over 50 ms acquired at 0.5 Hz and a holding potential of 0 mV. Inward and outward current amplitudes were extracted at −80 mV and +80 mV and were normalized to cell size as pA/pF. Capacitance was measured using the automated capacitance cancellation function of EPC10. Patch pipettes were made of borosilicate glass (Science Products) and had resistance 2–3.5 MΩ.
Unless stated otherwise, a standard extracellular solution contained (in mM): 140 NaCl, 2.8 KCl, 1 CaCl2, 2 MgCl2, 10 HEPES-NaOH, and 11 glucose (all from Sigma-Aldrich), pH 7.2. Effects of NS8593 (Tocris), 2-aminoethyl diphenylborinate (2-APB; Sigma-Aldrich) and naltriben (Tocris) were examined by adding the compounds to the standard extracellular solution. A divalent cation-free (DVF) extracellular solution contained (in mM) 140 NaCl, 2.8 KCl, 11 glucose, 5 Na-EDTA and 10 HEPES-NaOH, pH 7.2. In assessment of ion permeation profiles of mTRPM6 and mTRPM7, the extracellular solutions contained: 10 mM HEPES-NaOH, 260 mM mannitole and 10 mM of individual divalent cations (ZnCl2, MgCl2, CaCl2 or BaCl2), and were adjusted to pH 7.0 (to prevent the precipitation of ZnCl2). Solutions were adjusted to 290 mOsm using a Vapro 5520 osmometer (Wescor Inc).
The standard Mg2+-free intracellular ([Mg2+]i) pipette solution contained (in mM): 120 Cs-glutamate, 8 NaCl, 10 Cs-EGTA, 5 Cs-EDTA, 10 HEPES-CsOH, pH 7.2. In some measurements, we varied free [Mg2+]i levels as follows. A nominally [Mg2+]i-free intracellular solution contained (in mM) 140 Cs-glutamate, 8 NaCl, 10 HEPES-CsOH, pH 7.2. A pipette solution with 1 µM free [Mg2+]i comprised (in mM): 140 Cs-glutamate, 8 NaCl, 0.0016 MgCl2, 10 Cs-EGTA, 10 HEPES-CsOH, pH 7.2. An intracellular solution with 2 mM free [Mg2+]i contained (in mM): 120 Cs-glutamate, 8 NaCl, 2 Cs-EDTA, 10 HEPES-CsOH, 4 MgCl2, pH 7.2. A pipette solution with 210 µM Mg·ATP and 10 µM free [Mg2+]i contained (in mM): 140 Cs-glutamate, 8 NaCl, 3 Cs-EDTA, 10 HEPES-CsOH, 2.5 Mg·ATP (Sigma-Aldrich), pH 7.2. Concentrations of [Mg·ATP]i and free [Mg2+]i were calculated using WebMaxC (maxchelator.stanford.edu).
Data are presented as means ± standard error of the mean (SEM). Data showed normal distribution. Unless indicated differently, data were compared by a two-tailed t-test. For multiple comparisons in Fig. 2D, Supplementary Fig. S7, and Supplementary Fig. S9, ANOVA (GraphPad Prism 6.0 software) was used. Significance was accepted at P ≤ 0.05.
To determine [Mg2+]i and [Mg·ATP]i dose responses, the intracellular pipette solutions were prepared as outlined in Supplementary Table S1 and Supplementary Table S2, respectively. To determine IC50 values for inhibitory effects of [Mg·ATP]i and [Mg2+]i on mTRPM6 and mTRPM7 currents, data were fitted with the following equation:
with E being the effect/current at a given concentration c of inhibitor, Emin the minimal effect/current, Emax the maximally achievable effect, IC50 the half-maximal concentration and h the Hill factor. Statistical analysis of dose-response curves and IC50 values (Fig. 8C and Fig. 9C) was performed using the extra sum-of-squares F test with the threshold P ≤ 0.05 (GraphPad Prism 6.0).
Chubanov, V. & Gudermann, T. Trpm6. Handbook of experimental pharmacology 222, 503–520, doi:10.1007/978-3-642-54215-2_20 (2014).
Fleig, A. & Chubanov, V. Trpm7. Handbook of experimental pharmacology 222, 521–546, doi:10.1007/978-3-642-54215-2_21 (2014).
Schmitz, C. et al. Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell 114, 191–200 (2003).
Sahni, J. & Scharenberg, A. M. TRPM7 ion channels are required for sustained phosphoinositide 3-kinase signaling in lymphocytes. Cell metabolism 8, 84–93, doi:10.1016/j.cmet.2008.06.002 (2008).
Ryazanova, L. V. et al. TRPM7 is essential for Mg(2+) homeostasis in mammals. Nature communications 1, 109, doi:10.1038/ncomms1108 (2010).
Wei, C. et al. Calcium flickers steer cell migration. Nature 457, 901–905, doi:10.1038/nature07577 (2009).
Visser, D. et al. TRPM7 triggers Ca2+ sparks and invadosome formation in neuroblastoma cells. Cell calcium 54, 404–415, doi:10.1016/j.ceca.2013.09.003 (2013).
Faouzi, M., Kilch, T., Horgen, F. D., Fleig, A. & Penner, R. The TRPM7 channel kinase regulates store-operated calcium entry. The Journal of physiology, doi:10.1113/JP274006 (2017).
Krapivinsky, G., Krapivinsky, L., Manasian, Y. & Clapham, D. E. The TRPM7 chanzyme is cleaved to release a chromatin-modifying kinase. Cell 157, 1061–1072, doi:10.1016/j.cell.2014.03.046 (2014).
Su, L. T. et al. TRPM7 regulates cell adhesion by controlling the calcium-dependent protease calpain. The Journal of biological chemistry 281, 11260–11270, doi:10.1074/jbc.M512885200 (2006).
Su, L. T. et al. TRPM7 regulates polarized cell movements. The Biochemical journal 434, 513–521, doi:10.1042/BJ20101678 (2011).
Clark, K. et al. TRPM7, a novel regulator of actomyosin contractility and cell adhesion. The EMBO journal 25, 290–301, doi:10.1038/sj.emboj.7600931 (2006).
Clark, K. et al. TRPM7 regulates myosin IIA filament stability and protein localization by heavy chain phosphorylation. Journal of molecular biology 378, 790–803, doi:10.1016/j.jmb.2008.02.057 (2008).
Sahni, J., Tamura, R., Sweet, I. R. & Scharenberg, A. M. TRPM7 regulates quiescent/proliferative metabolic transitions in lymphocytes. Cell cycle 9, 3565–3574, doi:10.4161/cc.9.17.12798 (2010).
Nadler, M. J. et al. LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature 411, 590–595, doi:10.1038/35079092 (2001).
Tani, D., Monteilh-Zoller, M. K., Fleig, A. & Penner, R. Cell cycle-dependent regulation of store-operated I(CRAC) and Mg2+-nucleotide-regulated MagNuM (TRPM7) currents. Cell calcium 41, 249–260, doi:10.1016/j.ceca.2006.07.004 (2007).
Jin, J. et al. Deletion of Trpm7 disrupts embryonic development and thymopoiesis without altering Mg2+ homeostasis. Science 322, 756–760, doi:10.1126/science.1163493 (2008).
McNeill, M. S. et al. Cell death of melanophores in zebrafish trpm7 mutant embryos depends on melanin synthesis. The Journal of investigative dermatology 127, 2020–2030, doi:10.1038/sj.jid.5700710 (2007).
Jin, J. et al. The channel kinase, TRPM7, is required for early embryonic development. Proceedings of the National Academy of Sciences of the United States of America 109, E225–233, doi:10.1073/pnas.1120033109 (2012).
Sah, R. et al. Ion channel-kinase TRPM7 is required for maintaining cardiac automaticity. Proceedings of the National Academy of Sciences of the United States of America 110, E3037–3046, doi:10.1073/pnas.1311865110 (2013).
Sah, R. et al. Timing of myocardial trpm7 deletion during cardiogenesis variably disrupts adult ventricular function, conduction, and repolarization. Circulation 128, 101–114, doi:10.1161/CIRCULATIONAHA.112.000768 (2013).
Kaitsuka, T. et al. Inactivation of TRPM7 kinase activity does not impair its channel function in mice. Scientific reports 4, 5718, doi:10.1038/srep05718 (2014).
Ryazanova, L. V. et al. Elucidating the role of the TRPM7 alpha-kinase: TRPM7 kinase inactivation leads to magnesium deprivation resistance phenotype in mice. Scientific reports 4, 7599, doi:10.1038/srep07599 (2014).
Stritt, S. et al. Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg(2+) homeostasis and cytoskeletal architecture. Nature communications 7, 11097, doi:10.1038/ncomms11097 (2016).
Jansen, C. et al. The coiled-coil domain of zebrafish TRPM7 regulates Mg.nucleotide sensitivity. Scientific reports 6, 33459, doi:10.1038/srep33459 (2016).
Monteilh-Zoller, M. K. et al. TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. The Journal of general physiology 121, 49–60 (2003).
Zhang, Z. et al. The TRPM6 kinase domain determines the Mg.ATP sensitivity of TRPM7/M6 heteromeric ion channels. The Journal of biological chemistry 289, 5217–5227, doi:10.1074/jbc.M113.512285 (2014).
Runnels, L. W., Yue, L. & Clapham, D. E. The TRPM7 channel is inactivated by PIP(2) hydrolysis. Nature cell biology 4, 329–336, doi:10.1038/ncb781 (2002).
Mederos y Schnitzler, M., Waring, J., Gudermann, T. & Chubanov, V. Evolutionary determinants of divergent calcium selectivity of TRPM channels. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 22, 1540-1551, doi:10.1096/fj.07-9694com (2008).
Hermosura, M. C., Monteilh-Zoller, M. K., Scharenberg, A. M., Penner, R. & Fleig, A. Dissociation of the store-operated calcium current I(CRAC) and the Mg-nucleotide-regulated metal ion current MagNuM. J Physiol 539, 445–458 (2002).
Kozak, J. A., Kerschbaum, H. H. & Cahalan, M. D. Distinct properties of CRAC and MIC channels in RBL cells. J Gen Physiol 120, 221–235 (2002).
Friedman, M., Hatcher, G. & Watson, L. Primary hypomagnesaemia with secondary hypocalcaemia in an infant. Lancet 1, 703–705 (1967).
Milla, P. J., Aggett, P. J., Wolff, O. H. & Harries, J. T. Studies in primary hypomagnesaemia: evidence for defective carrier-mediated small intestinal transport of magnesium. Gut 20, 1028–1033 (1979).
Schlingmann, K. P. et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nature genetics 31, 166–170, doi:10.1038/ng889 (2002).
Walder, R. Y. et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nature genetics 31, 171–174, doi:10.1038/ng901 (2002).
Walder, R. Y. et al. Mice defective in Trpm6 show embryonic mortality and neural tube defects. Human molecular genetics 18, 4367–4375, doi:10.1093/hmg/ddp392 (2009).
Chubanov, V. et al. Epithelial magnesium transport by TRPM6 is essential for prenatal development and adult survival. eLife 5, doi:10.7554/eLife.20914 (2016).
Chubanov, V. et al. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proceedings of the National Academy of Sciences of the United States of America 101, 2894–2899, doi:10.1073/pnas.0305252101 (2004).
Chubanov, V. et al. Hypomagnesemia with secondary hypocalcemia due to a missense mutation in the putative pore-forming region of TRPM6. The Journal of biological chemistry 282, 7656–7667, doi:10.1074/jbc.M611117200 (2007).
Schmitz, C. et al. The channel kinases TRPM6 and TRPM7 are functionally nonredundant. The Journal of biological chemistry 280, 37763–37771, doi:10.1074/jbc.M509175200 (2005).
Suzuki, Y., Watanabe, M., Saito, C. T. & Tominaga, M. Expression of the TRPM6 in mouse placental trophoblasts; potential role in maternal-fetal calcium transport. J Physiol Sci 67, 151–162, doi:10.1007/s12576-016-0449-0 (2017).
Voets, T. et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. The Journal of biological chemistry 279, 19–25, doi:10.1074/jbc.M311201200 (2004).
Li, M., Jiang, J. & Yue, L. Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. The Journal of general physiology 127, 525–537, doi:10.1085/jgp.200609502 (2006).
Thebault, S. et al. Role of the alpha-kinase domain in transient receptor potential melastatin 6 channel and regulation by intracellular ATP. The Journal of biological chemistry 283, 19999–20007, doi:10.1074/jbc.M800167200 (2008).
Chubanov, V., Mederos y Schnitzler, M., Waring, J., Plank, A. & Gudermann, T. Emerging roles of TRPM6/TRPM7 channel kinase signal transduction complexes. Naunyn-Schmiedeberg’s archives of pharmacology 371, 334–341, doi:10.1007/s00210-005-1056-4 (2005).
Yamaguchi, H., Matsushita, M., Nairn, A. C. & Kuriyan, J. Crystal structure of the atypical protein kinase domain of a TRP channel with phosphotransferase activity. Molecular cell 7, 1047–1057 (2001).
Matsushita, M. et al. Channel function is dissociated from the intrinsic kinase activity and autophosphorylation of TRPM7/ChaK1. The Journal of biological chemistry 280, 20793–20803, doi:10.1074/jbc.M413671200 (2005).
Davis, M. I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29, 1046–1051, doi:10.1038/nbt.1990 (2011).
Chubanov, V. et al. Natural and synthetic modulators of SK (K(ca)2) potassium channels inhibit magnesium-dependent activity of the kinase-coupled cation channel TRPM7. British journal of pharmacology 166, 1357–1376, doi:10.1111/j.1476-5381.2012.01855.x (2012).
Brandao, K., Deason-Towne, F., Zhao, X., Perraud, A. L. & Schmitz, C. TRPM6 kinase activity regulates TRPM7 trafficking and inhibits cellular growth under hypomagnesic conditions. Cellular and molecular life sciences: CMLS 71, 4853–4867, doi:10.1007/s00018-014-1647-7 (2014).
Demeuse, P., Penner, R. & Fleig, A. TRPM7 channel is regulated by magnesium nucleotides via its kinase domain. The Journal of general physiology 127, 421–434, doi:10.1085/jgp.200509410 (2006).
Gupta, R. K., Gupta, P., Yushok, W. D. & Rose, Z. B. Measurement of the dissociation constant of MgATP at physiological nucleotide levels by a combination of 31P NMR and optical absorbance spectroscopy. Biochemical and biophysical research communications 117, 210–216 (1983).
Romani, A. M. Cellular magnesium homeostasis. Arch Biochem Biophys 512, 1–23, doi:10.1016/j.abb.2011.05.010 (2011).
Gunther, T. Concentration, compartmentation and metabolic function of intracellular free Mg2+. Magnesium research: official organ of the International Society for the Development of Research on Magnesium 19, 225–236 (2006).
Chubanov, V., Ferioli, S. & Gudermann, T. Assessment of TRPM7 functions by drug-like small molecules. Cell calcium, doi:10.1016/j.ceca.2017.03.004 (2017).
Hofmann, T. et al. Activation of TRPM7 channels by small molecules under physiological conditions. Pflugers Archiv: European journal of physiology 466, 2177–2189, doi:10.1007/s00424-014-1488-0 (2014).
Zhang, Z. et al. N-Myc-induced up-regulation of TRPM6/TRPM7 channels promotes neuroblastoma cell proliferation. Oncotarget 5, 7625–7634, doi:10.18632/oncotarget.2283 (2014).
Chubanov, V., Gudermann, T. & Schlingmann, K. P. Essential role for TRPM6 in epithelial magnesium transport and body magnesium homeostasis. Pflugers Archiv: European journal of physiology 451, 228–234, doi:10.1007/s00424-005-1470-y (2005).
Kaske, S. et al. TRPM5, a taste-signaling transient receptor potential ion-channel, is a ubiquitous signaling component in chemosensory cells. BMC neuroscience 8, 49, doi:10.1186/1471-2202-8-49 (2007).
Hofmann, T., Chubanov, V., Gudermann, T. & Montell, C. TRPM5 is a voltage-modulated and Ca(2+)-activated monovalent selective cation channel. Current biology: CB 13, 1153–1158 (2003).
Hofmann, T., Schaefer, M., Schultz, G. & Gudermann, T. Subunit composition of mammalian transient receptor potential channels in living cells. Proceedings of the National Academy of Sciences of the United States of America 99, 7461–7466, doi:10.1073/pnas.102596199 (2002).
Hofmann, T. et al. Activation of TRPM7 channels by small molecules under physiological conditions. Pflugers Archiv: European journal of physiology, doi:10.1007/s00424-014-1488-0 (2014).
Schafer, S. et al. Mibefradil represents a new class of benzimidazole TRPM7 channel agonists. Pflugers Archiv: European journal of physiology 468, 623–634, doi:10.1007/s00424-015-1772-7 (2016).
We thank Anna Erbacher and Dennis Faro for technical assistance. We thank Joost Hoenderop, Carsten Schmitz and Andrea Fleig for providing pCINeo-hTRPM6-IRES-GFP and HEK 293 T-REx cells stably expressing hTRPM6. V.C., S.Z. and T.G. were supported by the Deutsche Forschungsgemeinschaft, TRR 152.
The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Ferioli, S., Zierler, S., Zaißerer, J. et al. TRPM6 and TRPM7 differentially contribute to the relief of heteromeric TRPM6/7 channels from inhibition by cytosolic Mg2+ and Mg·ATP. Sci Rep 7, 8806 (2017). https://doi.org/10.1038/s41598-017-08144-1
This article is cited by
Nature Reviews Nephrology (2023)
Nature Communications (2023)
Intestinal hypomagnesemia in an Iranian patient with a novel TRPM6 variant: a case report and review of the literature
CEN Case Reports (2023)
Butyrate reduces cellular magnesium absorption independently of metabolic regulation in Caco-2 human colon cells
Scientific Reports (2022)
Acta Pharmacologica Sinica (2022)